Physician profile
Ali Moshiri
NPI 1679525786
$3,288.85
in general payments reported to CMS, 2019-2025
13 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2022: $548 · 2023: $1,286 · 2024: $990 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $749.65 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $515.21 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $493.67 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $489.62 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $303.45 | 2019-2024 | Ingrezza |
| Abbvie INC. | $256.32 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $183.68 | 2024-2025 | Cobenfy |
| Allergan, INC. | $103.24 | 2019 | |
| Neuronetics, INC. | $74.75 | 2019-2024 | Neurostar Tms Therapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $41.93 | 2022 | |
| Sunovion Pharmaceuticals INC. | $31.54 | 2022 | |
| Lundbeck LLC | $25.77 | 2024 | Rexulti |
| Indivior INC. | $20.02 | 2024 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Moshiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.